Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Bayer | Morning Blend
As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered Dietitian and Nutritionist Kelly ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer sees new drugs boosting return to growth in 2027, WSJ reports
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
FierceBiotech2d
JPM25: Bayer moves allogeneic cell therapy into phase 3 Parkinson's trial
Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...
Bayer plant doch keine Pharma-Großdeals, Fokus Schuldenabbau
Mit Blick auf die Neuausrichtung der Medikamentenpipeline von Bayer hatte Pharma-Chef Stefan Oelrich im letzten Januar ...
Foreign Policy3h
Bayer Phase 1 Menopause Issue Brief
Despite there currently being over 1 billion menopausal or postmenopausal women worldwide—a figure set to rise to 1.4 billion by 2030—menopause remains under-prioritized and under-resourced by ...
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...